• Publications
  • Influence
Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy
TLDR
Bcl-2 not only functions as an antiapoptotic protein, but also as an antiautophagy protein via its inhibitory interaction with Beclin 1, which may help maintain autophagy at levels that are compatible with cell survival, rather than cell death. Expand
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
TLDR
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure. Expand
Cardiac resynchronization in chronic heart failure.
TLDR
Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay. Expand
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary.
TLDR
The 2017-18 FACC/FACP/FCP/FCGC curriculum vitae were presented at a special session at the annual meeting of the American College of Cardiology in Los Angeles, California. Expand
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.
TLDR
It is indicated that circulating levels of tumor necrosis factor are increased in cachectic patients with chronic heart failure and that this elevation is associated with the marked activation of the renin-angiotensin system seen in patients with end-stage cardiac disease. Expand
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis
TLDR
It is shown that acute exercise induces autophagy in skeletal and cardiac muscle of fed mice and BCL2 is a crucial regulator of exercise- (and starvation)-induced autophagic induction in vivo, which may contribute to the beneficial metabolic effects of exercise. Expand
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
TLDR
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor. Expand
Effect of carvedilol on survival in severe chronic heart failure.
TLDR
The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial. Expand
The Seattle Heart Failure Model: Prediction of Survival in Heart Failure
TLDR
The Seattle Heart Failure Model provides an accurate estimate of 1-, 2-, and 3-year survival with the use of easily obtained clinical, pharmacological, device, and laboratory characteristics. Expand
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
TLDR
In patients with heart failure with preserved ejection fraction, LCZ696 reduced NT-proBNP to a greater extent than did valsartan at 12 weeks and was well tolerated; whether these effects would translate into improved outcomes needs to be tested prospectively. Expand
...
1
2
3
4
5
...